Wagner R - Search Results

1

Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain.

Deml L, Kratochwil G, Osterrieder N, Knüchel R, Wolf H, Wagner R. Deml L, et al. Among authors: wagner r. Virology. 1997 Aug 18;235(1):10-25. doi: 10.1006/viro.1997.8669. Virology. 1997. PMID: 9300033 Free article.

2

Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.

Wagner R, Fliessbach H, Wanner G, Motz M, Niedrig M, Deby G, von Brunn A, Wolf H. Wagner R, et al. Arch Virol. 1992;127(1-4):117-37. doi: 10.1007/BF01309579. Arch Virol. 1992. PMID: 1456888

3

Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.

Wagner R, Modrow S, Böltz T, Fliessbach H, Niedrig M, von Brunn A, Wolf H. Wagner R, et al. Arch Virol. 1992;127(1-4):139-52. doi: 10.1007/BF01309580. Arch Virol. 1992. PMID: 1456889

4

Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.

Schirmbeck R, Deml L, Melber K, Wolf H, Wagner R, Reimann J. Schirmbeck R, et al. Among authors: wagner r. Vaccine. 1995 Jun;13(9):857-65. doi: 10.1016/0264-410x(94)00038-o. Vaccine. 1995. PMID: 7483809

5

Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles.

Wagner R, Deml L, Fliessbach H, Wanner G, Wolf H. Wagner R, et al. Virology. 1994 Apr;200(1):162-75. doi: 10.1006/viro.1994.1175. Virology. 1994. PMID: 7510434 Free article.

6

Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.

Wagner R, Böltz T, Deml L, Modrow S, Wolf H. Wagner R, et al. J Gen Virol. 1993 Jul;74 ( Pt 7):1261-9. doi: 10.1099/0022-1317-74-7-1261. J Gen Virol. 1993. PMID: 7687647 Free article.

7

Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).

Osterrieder N, Wagner R, Brandmüller C, Schmidt P, Wolf H, Kaaden OR. Osterrieder N, et al. Among authors: wagner r. Virology. 1995 Apr 20;208(2):500-10. doi: 10.1006/viro.1995.1181. Virology. 1995. PMID: 7747423 Free article.

8

Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.

Wagner R, Deml L, Schirmbeck R, Reimann J, Wolf H. Wagner R, et al. Behring Inst Mitt. 1994 Dec;(95):23-34. Behring Inst Mitt. 1994. PMID: 7755506 Review.

9

[Current advances in HIV pathogenesis. Results of therapy and vaccine development].

Wagner R, Mayer J, Wolf H. Wagner R, et al. Dtsch Med Wochenschr. 1995 May 19;120(20):728-36. doi: 10.1055/s-2008-1055401. Dtsch Med Wochenschr. 1995. PMID: 7758413 Review. German. No abstract available.

10

Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies.

Wagner R, Deml L, Wolf H. Wagner R, et al. Antibiot Chemother (1971). 1994;46:48-61. doi: 10.1159/000423633. Antibiot Chemother (1971). 1994. PMID: 7826039 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,106 results

Search Page

Filters